Kidney function and estimated vascular risk in patients with primary dyslipidemia

Open Cardiovascular Medicine Journal

Volumn 3, Issue , 2009, Pages 57-68

  Tziomalos, Konstantinos ^a   Ganotakis, Emmanuel S ^b   Gazi, Irene F ^c   Nair, Devaki R ^d   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; Creatinine; Estimated glomerular filtration rate; Framingham risk score; Vascular risk

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URATE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 77953446026     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192400903010057     Document Type: Article

References (112)

1. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481-1492 (Pubitemid 29451714)
2. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. american heart association science advisory and coordinating committee. Circulation 2002; 106: 388-391 (Pubitemid 34778969)
3. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414
4. Grundy SM. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 1999; 100: 988-998 (Pubitemid 29407181)
5. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362
6. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster [PROCAM] study. Circulation 2002; 105: 310-315 (Pubitemid 34106178)
7. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998; 97: 1876-1887 (Pubitemid 28213637)
8. Jurgensen JS. The value of risk scores. Heart 2006; 92: 1713-1714
9. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-1353 (Pubitemid 38387819)
10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565 (Pubitemid 35315836)
11. Astor BC, Hallan SI, Miller ER, III, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167: 1226-1234 (Pubitemid 351670638)
12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305 (Pubitemid 39268908)
13. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006; 27: 1245-1250 (Pubitemid 43752396)
14. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-483 (Pubitemid 47343557)
15. Ajani UA, Ford ES, McGuire LC. Distribution of lifestyle and emerging risk factors by 10-year risk for coronary heart disease. Eur J Cardiovasc Prev Rehabil 2006; 13: 745-752 (Pubitemid 44454847)
16. Cao JJ, Biggs ML, Barzilay J, et al. Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. Atherosclerosis 2008; 197: 806-813
17. Weiner DE, Tighiouart H, Griffith JL, et al. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med 2007; 120: 552-558 (Pubitemid 46764619)
18. Ganotakis ES, Gazi IF, Papadakis JA, Jagroop IA, Nair DR, Mikhailidis DP. The relationship between circulating fibrinogen and lipoprotein [a] levels in patients with primary dyslipidemia. Clin Appl Thromb Hemost 2007; 13: 35-42. (Pubitemid 44905281)
19. Ganotakis ES, Vrentzos GE, Gazi IF, et al. Fibrinogen, lipoprotein [a], albumin and bilirubin [F-L-A-B] levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007; 21: 685-694 (Pubitemid 47232673)
20. Koenig W, Rosenson RS. Acute-phase reactants and coronary heart disease. Semin Vasc Med 2002; 2: 417-428
21. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196 (Pubitemid 38802622)
22. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
23. Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13: 1647-1659
24. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 117-141
25. Athyros VG, Tziomalos K, Mikhailidis DP, et al. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007; 8: 2267-2277
26. Mikhailidis DP, Spyropoulos KA. The effect of tamoxifen on lipid and haemostatic predictors of ischaemic heart disease. J Drug Dev Clin Pract 1996; 8: 19-24. (Pubitemid 26127467)
27. Tziomalos K, Athyros VG, Mikhailidis DP. Fish oils and vascular disease prevention: an update. Curr Med Chem 2007; 14: 2622-2628 (Pubitemid 350018474)
28. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009; 35: 175-184
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
30. Brosius FC, III, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006; 114: 1083-1087 (Pubitemid 44358886)
31. Kusuoka H, Hoffman JI. Advice on statistical analysis for Circulation Research. Circ Res 2002; 91: 662-671 (Pubitemid 35204948)
32. Meguid EN, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340 (Pubitemid 40139112)
33. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147 (Pubitemid 38129105)
34. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850 (Pubitemid 38543772)
35. Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 2008; 23: 1265-1273 (Pubitemid 351767507)
36. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278: 2069-2074 (Pubitemid 28016228)
37. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
38. Raymond NT, Zehnder D, Smith SC, Stinson JA, Lehnert H, Higgins RM. Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age. Nephrol Dial Transplant 2007; 22: 3214-3220 (Pubitemid 350202561)
39. Stevens PE, O'Donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-99 (Pubitemid 47014451)
40. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation [GREACE] Study. Nephrol Dial Transplant 2007; 22: 118-127
41. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation [GREACE] study. J Clin Pathol 2004; 57: 728-734 (Pubitemid 38901488)
42. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557-1563 (Pubitemid 39297976)
43. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295 (Pubitemid 39258422)
44. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555-562
45. Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18: 2766-2772 (Pubitemid 47531204)
46. Pasqualini L, Schillaci G, Pirro M, et al. Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease. J Intern Med 2007; 262: 668-677 (Pubitemid 350135191)
47. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997; 28: 557-563 (Pubitemid 27118377)
48. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006; 67: 224-228 (Pubitemid 44305403)
49. Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007; 38: 3127-3132 (Pubitemid 350175725)
50. de Vinuesa SG, Ortega M, Martinez P, Goicoechea M, Campdera FG, Luno J. Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. Kidney Int Suppl 2005; S44-S47. (Pubitemid 40019215)
51. Paraskevas KI, Hamilton G, Cross JM, Mikhailidis DP. Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract 2008; 108: c56-c66. (Pubitemid 351253446)
52. Daskalopoulou SS, Pathmarajah M, Kakkos SK, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J 2008; 72: 441-448 (Pubitemid 351600640)
53. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6: 93-107.
54. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 2006; 166: 1884-1891 (Pubitemid 44455172)
55. Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50: 217-224 (Pubitemid 47031564)
56. Cirillo M, Anastasio P, De Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 2005; 20: 1791-1798 (Pubitemid 41222590)
57. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-937 (Pubitemid 40040976)
58. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16: 763-773 (Pubitemid 41725113)
59. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a metaanalysis. Am J Kidney Dis 2002; 40: 221-226 (Pubitemid 34827638)
60. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060 (Pubitemid 40664306)
61. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179 (Pubitemid 46105715)
62. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421 (Pubitemid 38406982)
63. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study [WOSCOPS]. Circulation 1998; 97: 1440-1445
64. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327: 1267. (Pubitemid 37487285)
65. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis 2005; 181: 93-100. (Pubitemid 40804698)
66. Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003; 24: 1903-1911 (Pubitemid 37322699)
67. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006; 92: 1752-1759 (Pubitemid 44851316)
68. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-458
69. Vrentzos GE, Papadakis JA, Ganotakis ES, et al. Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. Int J Clin Pract 2007; 61: 1643-1653 (Pubitemid 47404397)
70. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets [TNT] study. Clin J Am Soc Nephrol 2007; 2: 1131-1139
71. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-178 (Pubitemid 40982298)
72. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016 (Pubitemid 36695042)
73. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-617 (Pubitemid 37288068)
74. Youssef F, Gupta P, Mikhailidis DP, Hamilton G. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 2005; 56: 279-287 (Pubitemid 40656430)
75. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62. (Pubitemid 38082539)
76. Youssef F, Seifalian AM, Jagroop IA, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness [IMT]. Eur J Vasc Endovasc Surg 2002; 23: 358-364 (Pubitemid 41079449)
77. Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 2006; 57: 65-71.
78. Kakafika A, Liamis G, Elisaf M, Mikhailidis D. Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 2001; 17: 230-231 (Pubitemid 34003126)
79. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124
80. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-987
81. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin [10 mg] for statin intolerant high-risk patients. Am J Cardiol 2008; 101: 483-485 (Pubitemid 351199439)
82. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-2192 (Pubitemid 350246604)
83. Sweny P, Wheeler DC, Lui SF, et al. Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant 1989; 4: 1070-1075 (Pubitemid 20135467)
84. Lauretani F, Semba RD, Bandinelli S, et al. Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 2008; 54: 475-481 (Pubitemid 351348158)
85. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine [ADMA] and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009;
86. Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT [Slovenia [SI] Statin Plus Ezetimibe in Cholesterol Treatment] monitoring of clinical practice study. Curr Med Res Opin 2008; 24: 2467-2476
87. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15: 1993-1999
88. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002; 53: 273-277 (Pubitemid 34525864)
89. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002; 7: 219-226 (Pubitemid 35471357)
90. Tziomalos K, Athyros VG. Fenofibrate: a novel formulation [Triglide] in the treatment of lipid disorders: a review. Int J Nanomedicine 2006; 1: 129-147
91. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005; 3: 87-98.
92. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 2001; 16: 1301. (Pubitemid 32547398)
93. Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002; 57: 407-408 (Pubitemid 34308831)
94. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006. (Pubitemid 41803111)
95. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92: 536-541
96. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus [the FIELD study]: randomised controlled trial. Lancet 2005; 366: 1849-1861.
97. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study [DAIS]. Am J Kidney Dis 2005; 45: 485-493 (Pubitemid 40341327)
98. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT [Treating to New Targets] study. J Am Coll Cardiol 2008; 51: 1448-1454
99. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 2007; 49: 373-382 (Pubitemid 46320760)
100. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360: 7-22. (Pubitemid 34756487)
101. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm [ASCOT-LLA]: a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158 (Pubitemid 36398384)
102. Baigent C, Landry M. Study of Heart and Renal Protection [SHARP]. Kidney Int Suppl 2003; S207-S210. (Pubitemid 36513411)
103. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66: 1123-1130 (Pubitemid 39121018)
104. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation [GREACE] study. Am J Kidney Dis 2004; 43: 589-599 (Pubitemid 38401873)
105. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
106. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426 (Pubitemid 32681484)
107. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-975 (Pubitemid 41170264)
108. Karagiannis A, Mikhailidis DP, Tziomalos K, Kakafika AI, Athyros VG. Has the time come for a new definition of microalbuminuria? Curr Vasc Pharmacol 2008; 6: 81-83
109. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002; 61: 2165-2175 (Pubitemid 34539334)
110. Cirillo M, Lanti MP, Menotti A, et al. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med 2008; 168: 617-624
111. Foster MC, Hwang SJ, Larson MG, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167: 1386-1392 (Pubitemid 47052437)
112. Olsen MH, Wachtell K, Ibsen H, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24: 775-781 (Pubitemid 43771844)